The Vaccines Manufacturing and Innovation Centre (VMIC UK Ltd)

What The Vaccines Manufacturing and Innovation Centre (VMIC UK Ltd) does

The Vaccines Manufacturing and Innovation Centre (VMIC UK Ltd) is a UK-based non-profit organization founded in 2017 and headquartered in Oxford, according to the supplied firmographic data. Its stated mission is to provide vaccine process development, clinical manufacturing, and pandemic surge capacity — positioning it as a biomanufacturing infrastructure provider serving the UK public-health and vaccine-development ecosystem.

The company's described core activity spans the early-to-mid stages of the vaccine value chain: process development (upstream and downstream bioprocess work), clinical-stage Good Manufacturing Practice (GMP) manufacturing, and the ability to scale up production rapidly in response to pandemic demand. As a non-profit entity, VMIC's revenue mechanics are not disclosed in the supplied data; no pricing model, customer list, funding rounds, or commercial contracts are present, suggesting the operating model is likely grant- or government-funded rather than commercial.

The source data is materially incomplete. The company's own website (vmicuk.com) was observed returning unrelated Indonesian-language online gambling content (ROYALTOGEL) rather than corporate material, and no management team, financials, product portfolio, partnerships, or milestones could be extracted. The supplied employee-count field of 10,000+ is inconsistent with the otherwise empty data set and with the scale profile of a single-site non-profit vaccine manufacturing centre, and should be treated as unreliable. Any investment, partnership, or diligence conclusion must therefore be grounded in primary sources outside the supplied extract.

Name

The Vaccines Manufacturing and Innovation Centre (VMIC UK Ltd)

Website

https://vmicuk.com

Company type

Private

Founded year

2017

Headcount range

5,001–10,000 employees

Short description

VMIC UK Ltd is a UK non-profit founded in 2017 and headquartered in Oxford that provides vaccine process development, clinical manufacturing, and pandemic surge capacity to the UK public-health ecosystem.

Ownership category

akta.pro rank

Product category

Vaccine Manufacturing Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Vaccine Manufacturing & Fill-Finish (HLAIAEAJ)

akta.pro secondary industries

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Health Security, Pandemic Preparedness & Response (IHR, EID) (BPADAIAH), Pandemic Preparedness & Rapid-Response Vaccines (HLAIAEAF)

Keywords

• Vaccine manufacturing services
• Clinical manufacturing
• Pandemic surge capacity
• Vaccine process development
• Biopharmaceutical manufacturing

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Technology or R&D, Operations

Core offering

VMIC UK Ltd provides vaccine process development, clinical manufacturing, and pandemic surge capacity services. The company supports the development and clinical-stage production of vaccines from its Oxford facility, established to strengthen the UK's vaccine manufacturing and pandemic response capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Vaccine Process Development Process development services for vaccine candidates, supporting organizations seeking to design, optimize, and scale up vaccine manufacturing processes.
• Clinical Manufacturing Clinical-scale vaccine manufacturing services for organizations developing vaccine candidates, providing GMP-compliant production capacity for clinical trial supply.
• Pandemic Surge Capacity Surge manufacturing capacity designed to enable rapid scaling of vaccine production in response to pandemic events, supporting UK national preparedness requirements.

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Emerging players

• Bavarian Nordic: Vaccine developer and manufacturer with strong public-health and pandemic-preparedness positioning (e.g., smallpox/monkeypox vaccines). Comparable in mission alignment to public-sector pandemic readiness, though vertically integrated as a developer rather than a pure CDMO.

Direct peers

• AGC Biologics: CDMO providing viral vector, protein, and vaccine process development plus GMP manufacturing. Direct peer in clinical-stage vaccine CDMO work, particularly for viral-vector and recombinant platforms.
• Lonza: One of the world's largest biologics and vaccine CDMOs, offering mammalian and microbial-based vaccine process development and GMP manufacturing. Closely comparable service offering to VMIC with established pandemic-response contracts (e.g., Moderna).
• Catalent: Global vaccine and biologic CDMO providing process development, clinical manufacturing, and fill-finish services. Directly comparable to VMIC across the same vaccine manufacturing value chain, though at materially larger scale and with commercial (rather than non-profit) structure.
• Oxford Biomedica: Oxford-based cell and gene therapy / viral vector CDMO. A geographically proximate peer serving vaccine and viral-vector developers with process development and clinical manufacturing — overlapping directly with VMIC's Oxford cluster and service profile.

Broad incumbents

• WuXi Biologics: Global biologics CDMO with end-to-end vaccine and antibody development-to-manufacturing services. A broad incumbent that competes with VMIC for outsourced vaccine manufacturing work, particularly for international biotech sponsors.
• Samsung Biologics: Large-scale Korean biologics CDMO offering clinical and commercial vaccine manufacturing. Comparable in scale and contract-development model, though oriented toward larger commercial-stage clients than VMIC's clinical-stage focus.

Others

• CEPI (Coalition for Epidemic Preparedness Innovations): Global funder and coordinator of vaccine development against epidemic threats. Not a CDMO peer but the principal ecosystem counterparty VMIC would interface with for pandemic-preparedness contract funding — relevant for partnership and demand-flow analysis.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights3 records

Customer concentration

• LinkedInlinkedin.com/company/vmicuk

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Vaccines Manufacturing and Innovation Centre (VMIC UK Ltd)